PFS based on presence or absence genetic alterations. (A) PFS by unmutated vs mutated IGHV, (B) del(17p) clone size (<20% vs ≥20%), (C) 1 vs ≥2 TP53 mutations, and (D) unmutated vs mutated SF3B1. ∗In the multivariable analysis, no significance was observed. The multivariable analysis included the following variables: ≥2 prior therapies, unmutated IGHV, nodal size ≥5 cm, and >1 TP53 mutation.